Predictive implications of decreased CA19‐9 at 8 weeks during nab‐paclitaxel plus gemcitabine for the induction of second‐line chemotherapy for patients with advanced pancreatic cancer

BACKGROUND: Second‐line (2L) chemotherapy after nab‐paclitaxel plus gemcitabine (AG) is important for improving the survival of patients with advanced pancreatic cancer (APC). However, many patients fail to receive 2L chemotherapy because of rapid disease progression. Therefore, early recognition of...

Descripción completa

Detalles Bibliográficos
Autores principales: Iede, Kiyotsugu, Yamada, Terumasa, Kato, Ryo, Ueda, Masami, Tsuda, Yujiro, Nakashima, Shinsuke, Ohta, Katsuya, Matsuyama, Jin, Ikenaga, Masakazu, Tominaga, Shusei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941508/
https://www.ncbi.nlm.nih.gov/pubmed/32969199
http://dx.doi.org/10.1002/cnr2.1289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941508/
https://www.ncbi.nlm.nih.gov/pubmed/32969199
http://dx.doi.org/10.1002/cnr2.1289

Ejemplares similares